Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Combining genetics and molecular biomarkers for Alzheimer’s disease prognostication

Well refined polygenic risk scores (PRS) have been established that successfully discriminate between Alzheimer’s disease (AD) cases and controls and achieve a high prediction accuracy. Carlos Cruchaga, PhD, Washington University School of Medicine, St Louis, MO, shares his thoughts on how PRS should be combined with additional measures to form a valuable prognostic model. PRS reflect one’s background genetic risk, but do not fully predict age of onset, rate of progression, and resilience. Dr Cruchaga explains that combining PRS with molecular biomarkers and epigenetic data may enable accurate prognostication in the future. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.


CC has received research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare.